0001048477-01-500054.txt : 20011101
0001048477-01-500054.hdr.sgml : 20011101
ACCESSION NUMBER: 0001048477-01-500054
CONFORMED SUBMISSION TYPE: 424B2
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20011031
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC
CENTRAL INDEX KEY: 0001048477
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 680397820
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 424B2
SEC ACT: 1933 Act
SEC FILE NUMBER: 333-48800
FILM NUMBER: 1771070
BUSINESS ADDRESS:
STREET 1: 371 BEL MARIN KEYS BLVD
STREET 2: STE 210
CITY: NOVATO
STATE: CA
ZIP: 94949
BUSINESS PHONE: 4158846700
MAIL ADDRESS:
STREET 1: 371 BEL MARIN KEYS BLVD
STREET 2: STE 210
CITY: NOVATO
STATE: CA
ZIP: 94949
424B2
1
prospectus103101_424b2.txt
Rule 424(b)(2) Prospectus Supplement
Registration No. 333-48800
PROSPECTUS SUPPLEMENT No. 4
TO PROSPECTUS DATED August 16, 2001
541,093 Shares
BioMarin Pharmaceutical Inc.
Common Stock
---------------------
This Prospectus Supplement supplements information contained in that
certain Prospectus of BioMarin Pharmaceutical Inc. dated August 16, 2001
relating to the potential sale and issuance from time to time of up to 2,500,000
shares of BioMarin common stock. This Prospectus Supplement is not complete
without, and may not be delivered or utilized except in connection with, the
Prospectus, including any amendments or supplements thereto. This Prospectus
Supplement is incorporated by reference into the Prospectus. You should read
this Prospectus Supplement and the accompanying Prospectus carefully before you
invest. Both documents contain information you should consider carefully before
making your investment decision.
See "Risk Factors" beginning on page 5 of the Prospectus to read about
risks that you should consider before buying shares of our common stock.
--------------------------
You should rely only on the information provided or incorporated by
reference in this Prospectus Supplement and the Prospectus. We have not
authorized anyone else to provide you with different information. You should not
assume that the information in this Prospectus Supplement is accurate as of any
date other than the date on the front of this Prospectus Supplement.
--------------------------
NEITHER THE SECURITIES EXCHANGE COMMISSION NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR PASSED UPON THE
ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A
CRIMINAL OFFENSE.
--------------------------
The date of this Prospectus Supplement is October 31, 2001
TABLE OF CONTENTS
PROSPECTUS SUPPLEMENT
Plan of Distribution.........................................................S-1
PROSPECTUS
Summary........................................................................1
The Offering...................................................................3
Forward Looking Statements.....................................................4
Risk Factors...................................................................5
Use of Proceeds...............................................................16
Plan of Distribution..........................................................17
Legal Matters.................................................................19
Experts.......................................................................19
The following information supplements the information set forth in the
Prospectus.
PLAN OF DISTRIBUTION
On October 31, 2001, we will issue and sell 541,093 shares of our common
stock to Acqua Wellington North American Equities Fund, Ltd. pursuant to this
prospectus supplement and pursuant to the terms of the common stock purchase
agreement entered into between Acqua Wellington and us on August 15, 2001. The
common stock will be purchased at a negotiated purchase price of $10.1646 per
share. We will pay Reedland Capital Partners, an Institutional Division of
Financial West Group, a fee of $55,000 in consideration of placement agent
services related to this purchase by Acqua Wellington. We will not pay any other
compensation in conjunction with the sale of these shares of our common stock.
See "Plan of Distribution" beginning on page 17 of the prospectus.